OBJECTIVE To investigate clinical efficacy and safety of 2 certolizumab pegol (CZP) maintenance dosing regimens plus methotrexate (MTX) in active rheumatoid arthritis (RA) patients achieving the American College of Rheumatology 20% improvement criteria (ACR20) after the CZP 200 mg every 2 weeks open-label run-in period. METHODS DOSEFLEX (dosing flexibility) was a double-blind, placebo-control...

National Vocational Qualifications (NVQs) were developed out of a plethora of initiatives implemented between 1960 and 1990. The format of NVQs was initially based on a hierarchical task analysis of job functions within the hospitality and catering industry, conducted as part of the CATERBASE project, which was commissioned by the Manpower Services Commission in the mid-1980s. This issues paper...

This paper examines institutional and regulatory aspects of sustainable transport from a cross-national perspective. While institutions appear to play an important role in the economic success of many countries, it is not so clear that they also support sustainable development. A number of examples of the role of institutions in transport are discussed. Particular attention is focused among oth...

Ustekinumab (UST) targets the common subunit (p40) of interleukins-12/23,1Benson J.M. Peritt D. Scallion B.J. et al.Discovery and mechanism ustekinumab: a human monoclonal antibody targeting interleukin-12 interleukin-23 for treament immune-mediated disorders.MAbs. 2011; 3: 535-545Crossref PubMed Scopus (171) Google Scholar,2Singh S. Fumery M. Sandborn W.J. al.Systematic review network meta-ana...

The internet raises substantial challenges for policy makers in regulating gambling harm. proliferation of advertising on Twitter is one such challenge. However, the sheer scale renders it extremely difficult to investigate using conventional techniques. In this article, authors present three U.K. studies both big data analytics and manual content analysis explore volume ads, age engagement fol...

BACKGROUND Subcutaneous peginterferon beta-1a provided clinical benefits at Year 1 (placebo-controlled period) of the 2-Year Phase 3 ADVANCE study in relapsing-remitting multiple sclerosis (RRMS). Here we report the effect of peginterferon beta-1a on brain magnetic resonance imaging (MRI) lesions, and no evidence of disease activity (NEDA; absence of clinical [relapses and 12-week confirmed dis...